Sean M. Healey & AMG Center for ALS


Spring 2026 newsletter: Clinical trials & observational research

At the Healey & AMG Center for ALS and the Kathy Garrett Research Center for ALS, people living with ALS are at the heart of all we do. Our researchers and clinicians work together with people living with ALS and their families to accelerate global discovery and innovation, expand access to research opportunities, and provide exceptional care. To support our work, please visit our website.

 

Dear friends,

With this newsletter, we shine a spotlight on research initiatives across the Sean M. Healey & AMG Center for ALS to accelerate the development of effective treatments and increase access to research opportunities for people living with ALS. These include:


  • Accelerated Centers of Enrollment (ACE) program, which is making enrollment faster and more efficient for participants in ALS clinical trials, EAPs, and observational studies


  • Access for ALL in ALS Consortium (ALL ALS), an observational research program to advance understanding of ALS and expedite clinical trials


  • HEALEY ALS Platform Trial and Healey ALS MyMatch, our pioneering clinical trial platforms that are transforming ALS therapy development


We thank our entire ALS community for participating in these and other bold research programs in the Healey & AMG Center. Your dedication to finding new therapies gives us hope in beating this devastating disease.


As ALS Awareness Month comes to a close, we are grateful for your continued support and advocacy which inspire our efforts — not only this past month, but all year long.


Warmly,


Merit Cudkowicz, MD, MSc and James Berry, MD, MPH

Research spotlights

 

Accelerating access to ALS clinical research

In 2024, we launched the Accelerated Centers of Enrollment (ACE) initiative - a collaborative effort with Northwestern Medicine and the University of Minnesota supported by philanthropic foundations. This initiative was designed to increase access to ALS clinical research by overcoming historical enrollment delays. In the first few months of 2026, the Healey & AMG Center at Mass General Brigham enrolled the first participants in 3 ALS clinical trials, including the PREVAiLS study, VectorY and the HEALEY ALS Platform Trial. By utilizing a novel funding model to provide dedicated enrollment teams, the ACE initiative has already doubled enrollment rates and significantly reduced participant wait times. Our goal is to ensure that no person living with ALS is told to wait to participate in research. By strengthening research infrastructure and expanding site capacity and optimizing operational processes, we will continue to bring research opportunities to people living with ALS as fast as possible.


Watch a video about ACE

ALL ALS Consortium

The Access for ALL in ALS Consortium (ALL ALS) is an actively enrolling, NIH-funded, observational ALS research program that aims to advance ALS understandings and accelerate treatment and clinical trial development. Let’s explore some recent ALL ALS milestones:

As of May 8th, ALL ALS has enrolled a total of 1,615 participants, including 786 people living with ALS, 335 people living without ALS (controls), and 494 people at genetic risk.


ALL ALS has enrolled participants from all 50 U.S. states and Puerto Rico.


ALL ALS maintains their commitment to research accessibility with over 1,100 home phlebotomy visits having been conducted over the last 18 months.

ALL ALS continues to develop their digital biomarker study components:

  • 93 participants have been enrolled in the DIGITIZE assessments component, which collects digital health information through ankle and wrist activity monitors.
  • 5,032 speech samples have been collected.
  • 10,239 digital surveys, which are focused on a wide variety of important topics, such as environmental history, have been collected from participants living with ALS.


ALL ALS has initiated genomic, neurofilament, and other large-scale biomarker analyses on their collected biological samples.


The Spanish ALL ALS website has officially launched to increase engagement among the Spanish-speaking ALS community. 

Stay up to date with ALL ALS:

  • Sign up to their quarterly community newsletter: Newsletter Sign-Up
  • Join their webinar registry: Webinar Registry
  • Follow the ALL ALS Instagram (@all_als_) or Facebook (ALL ALS)

Strategic research initiatives

 

HEALEY ALS Platform Trial

Enrollment in Regimen I


We’re pleased to share encouraging progress from the HEALEY ALS Platform Trial. Enrollment in Regimen I evaluating NUZ-001 by Neurizon Therapeutics is ahead of expectations, moving at a pace we have not seen before. This is exciting news for the ALS community—faster enrollment helps us reach answers more quickly for people living with ALS. We are deeply grateful to the participants, families, clinical teams, and partners who are making this possible.

 

To support this strong momentum, we are increasing the size of Regimen I from 160 to 240 participants. Expanding the number of participants will help ensure the study remains robust and continues to generate meaningful results.


Read more in Neurizon’s announcement here


Regimen I Science community webinar and brochure


Interested in learning more about the science behind NUZ-001? Watch a recording of this webinar with Regimen I co-lead investigators James Berry, MD, MPH and Michael Weiss, MD and scientists from Neurizon Therapeutics. They discussed the science of Regimen I and answered questions from the audience.

Healey ALS MyMatch

Healey ALS MyMatch is an early-phase biomarker-driven program. Below are a few updates on its trials.


  • We expect top-line results from the ACACIA Trial in the summer of 2026
  • We are excited to share that we are preparing for enrollment for the BANYAN Trial with Tiziana Life Sciences
  • We’re pleased to announce that we contracted with Keros Therapeutics, Inc. to design a new Healey ALS MyMatch trial evaluating rinvatercept (KER-065). Read the press release

Latest publications

Experimental Therapy Shows Safety and Signals of Clinical Benefit in ALS | Mass General Brigham


The investigational therapy PrimeC has shown safety and early signals of clinical benefit in people living with ALS. The findings come from the PARADIGM study, led by teams at Mass General Brigham Neuroscience Institute and Barrow Neurological Institute. 

Bridging the gap: understanding participation barriers in ALS clinical trials through on-the-ground insights


In this study published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration by Scirocco, E., Pogemiller Bulat, A., Carey, J. R. et al., researchers went into the community to interview people living with ALS, their caregivers, and health care providers to learn more about barriers to research participation. The study found that establishing trusted relationships with healthcare providers and improving accessibility to information about ALS trials could help boost enrollment.


Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial


In this post hoc analysis of the HEALEY ALS Platform Trial, published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, pridopidine showed positive signals functional measures including speech in a subgroup of patients with definite/probable ALS and early disease. These findings directly informed the design of the phase 3 pridopidine trial that is now enrolling.

Patient information

Research access


Our research programs are dedicated to advancing ALS science, uncovering its underlying causes, and ultimately discovering effective treatments for this disease. If you would like to learn more about how to stay connected to ALS research, please reach out to our research access nurses, Kiersten Pease or Judi Carey at mghalsresearch@mgb.org. You can also visit our clinical trials page here. We are deeply grateful to all past, current, and future participants who are helping to accelerate research and drive the search for life-saving therapies.

Study Spotlights


Trial of Pridopidine Phase 3

  • Purpose of Trial: To evaluate if the investigational study drug (pridopidine) may slow disease progression and improve speech, breathing, and survival.


Study of Speech, Social Connectedness, and Well-Being Outcomes in ALS

  • Purpose of Study: To understand the impact of ALS and associated speech impairments on social connectedness and quality of life.


Clinical research webpage

Upcoming Healey & AMG Center webinars


Thursday, May 28, 5:00 pm ET: HEALEY ALS Platform Trial Update

Thursday, June 25, 5:00 pm ET: HEALEY ALS Platform Trial Update

In the community

Harpoon 5-miler

Members of the Healey & AMG Center were proud to participate in the 25th annual Harpoon 5-Miler on Saturday, May 16, joining fellow members of the ALS community along the spectator-lined streets of the Boston Seaport. Since its inception in 2001, this community event has raised more than $3 million in support of ALS research and care initiatives across Massachusetts and beyond. With more than 4,500 participants this year, the race was a powerful reminder of the unity, camaraderie, and collective commitment driving progress in the fight against ALS.

4th Annual Team Goose Hockey Tournament

On June 13, Team Goose will host their fourth annual hockey tournament, in Wayne, NJ, bringing together players, families, and supporters united by a shared commitment to finding a cure for ALS. Organized by Gary Ragusa Jr., in honor of his father, Team Goose aims to help improve people's lives through support, advocacy, and research funding. Funds raised through this great event will benefit ALS research at the Healey & AMG Center. 

2nd Annual Richard J. Wolnik Golf Tournament

On June 29, the Richard J. Wolnik Foundation for ALS Research will host their 2nd Annual Golf Tournament at Indian Ridge Country Club. Inspired by Dick Wolnik’s commitment to advancing progress, the event reflects a shared dedication to accelerating the most promising ALS research efforts at the Sean M. Healey & AMG Center for ALS. In addition to golf, there will be a silent auction and awards dinner. Visit the event website to learn more. 

Announcements and awards

The Angel Fund for ALS Research Awards Gift to Dr. James Berry and Mass General Brigham to Support Technology for Identifying Novel Biomarkers

The Angel Fund for ALS Research has generously pledged $335,000 to the Sean M. Healey & AMG Center for ALS to support Dr. James Berry’s research into the use of a new technology platform for identifying novel biomarkers. Founded in 1988, the Angel Fund is dedicated to supporting ALS research aimed at finding the cause, treatment, and cure for the disease.


This support from the Angel Fund will enable Dr. Berry and his team to identify novel biomarkers of ALS onset in genetically at-risk participants from the Dominantly Inherited ALS (DIALS) study. Biosamples will be analyzed using the Nucleic acid-Linked Immuno-Sandwich Assay (NULISA) platform, a new technology that can detect protein biomarkers. In the future, this will facilitate trials of experimental therapies aimed at preventing ALS.

Congratulations to Tim Green for Emmy Award


Congratulations to Tim Green and his team for receiving the Emmy Award for Outstanding Sports Feature: Long Form for their film, "Tim Green - A Voice Reclaimed." View the X announcement


In 2018, Tim Green started Tackle ALS in partnership with the Healey & AMG Center. Every dollar donated funds ALS research at the Healey & AMG Center, helping to accelerate the delivery of scientific discoveries to people living with ALS through innovative trial approaches. Learn more about Tackle ALS

MDA Wings Over Wallstreet

In recognition of her extraordinary leadership and contributions to advancing ALS research, Dr. Merit Cudkowicz will receive the 2026 Diamond Award at the Muscular Dystrophy Association’s Wings Over Wall Street gala on Thursday, June 4. The evening will celebrate the significant progress in ALS research, as well as the partnerships that continue to drive the field forward. For more information, please visit 2026 Wings Over Wall Street by Muscular Dystrophy Association.

Welcoming summer interns


We’re excited to welcome 7 summer interns working in the lab, clinic, biorepository, project management, and data management teams! Over the next 3 months, they will learn about ALS research and care and how clinical trials are structured and run. 

Glint of light in therapy for deadly ALS after decades of struggle


Merit Cudkowicz, MD, MSc, tells The Harvard Gazette how, after studying and treating ALS for three decades, recently published results from her research team’s clinical trial affirm her belief that “this illness can be stopped.”

 

Impact of philanthropy

Our work in the Sean M. Healey & AMG Center for ALS is accelerating therapeutic breakthroughs and improving holistic care for patients and their families. Our top priority is delivering research-informed care that truly makes a difference for people living with ALS. We focus on innovations that enhance comfort, independence, and access to vital programs — ensuring every patient and family receives the support they need throughout their journey. Your philanthropic support will help us continue our work to transform the lives of those living with ALS and bring us closer to a cure. Thank you for your consideration.

 

If you have questions or would like to learn more about how you can support the Sean M. Healey & AMG Center for ALS, please contact Emily Monteiro at emonteiro7@mgh.harvard.edu or visit https://www.massgeneral.org/neurology/als/support/.

 

Follow Mass General Neurology on social media to stay up to date with the

Sean M. Healey & AMG Center for ALS.

Facebook      LinkedIn      X
 
 

Patient & Family Resources

 
 

Latest News & Events

 
 

Research Opportunities